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NBS1, also known as NBN, plays an important role in maintaining genomic stability. Interestingly, 
rs2735383 G > C, located in a microRNA binding site in the 3′-untranslated region (UTR) of NBS1, 
was shown to be associated with increased susceptibility to lung and colorectal cancer. However, 
the relation between rs2735383 and susceptibility to breast cancer is not yet clear. Therefore, we 
genotyped rs2735383 in 1,170 familial non-BRCA1/2 breast cancer cases and 1,077 controls using 
PCR-based restriction fragment length polymorphism (RFLP-PCR) analysis, but found no association 
between rs2735383CC and breast cancer risk (OR = 1.214, 95% CI = 0.936–1.574, P = 0.144). Because 
we could not exclude a small effect size due to a limited sample size, we further analyzed imputed 
rs2735383 genotypes (r2 > 0.999) of 47,640 breast cancer cases and 46,656 controls from the Breast 
Cancer Association Consortium (BCAC). However, rs2735383CC was not associated with overall breast 
cancer risk in European (OR = 1.014, 95% CI = 0.969–1.060, P = 0.556) nor in Asian women (OR = 0.998, 
95% CI = 0.905–1.100, P = 0.961). Subgroup analyses by age, age at menarche, age at menopause, 
menopausal status, number of pregnancies, breast feeding, family history and receptor status also 
did not reveal a significant association. This study therefore does not support the involvement of the 
genotype at NBS1 rs2735383 in breast cancer susceptibility.
The DNA damage response (DDR) pathway maintains the stability of the human genome via a complex network 
of pathways integrating signal transduction, regulation of the cell cycle and repair of DNA. Double-strand breaks 
(DSBs), a particularly severe form of DNA damage, arise as a consequence of cell replication, programmed DNA 
rearrangements (i.e. meiosis and VDJ recombination) and exposure to carcinogens. When left unrepaired, DSBs 
may cause genomic instability, cell death and cancer1,2. In fact, mutations in genes involved in DSB repair, but 
also in the DDR pathway in general, are involved in the etiology of many human cancers. The two major repair 
pathways that mediate the repair of DSBs are the template-mediated homologous recombination repair pathway 
and the more error-prone non-homologous end-joining pathway3,4. The MRE11/RAD50/NBS1 complex is an 
important regulator of DSB repair through these pathways as this complex not only acts as a sensor of DSBs, but 
also recruits and activates the ATM protein to the break and activates it5. Activation of ATM, the central mediator 
of response to DSBs, initiates a cascade of signaling pathways involved in cell cycle checkpoint control, DNA 
repair and, when necessary, apoptosis by phosphorylation of p53, CHEK2, BRCA1, FANCD2 and NBS1 amongst 
others6.
The DDR plays an important role in susceptibility to breast cancer. In fact, all of the currently identified high- 
and moderate-risk breast cancer genes (i.e. BRCA1, BRCA2, CHEK2, ATM, NBS1 and PALB2) are involved in 
DNA repair7,8. As the majority of familial breast cancer risk is not yet attributable to known risk genes, this makes 
other genes encoding proteins involved in the DDR pathway attractive candidates for breast cancer susceptibility 
genes. The recent identification of the early DNA damage response gene MCPH1as a novel breast cancer suscep-
tibility gene illustrates that this hypothesis still holds9.
In this respect, the NBS1 gene is located at chromosome 8q21 and bi-allelic germline mutations in NBS1 
cause the chromosomal instability syndrome Nijmegen breakage syndrome10. In addition, heterozygous carriers 
of NBS1 mutations are at an increased risk to develop several types of cancer11. The NBS1 c.657del5 founder 
mutation is the most prevalent mutation implicated in Nijmegen breakage syndrome (i.e. 90%) and has its origin 
in the Slavic population12. The mutation confers an overall 2.5- to 3-fold increased cancer risk and is associated 
with increased risk for breast cancer, prostate cancer and lymphoma specifically13. Two other NBS1 mutations 
implicated in Nijmegen breakage syndrome are p.I171V and p.R215W. Although both mutations associate with 
an overall cancer risk of 4-fold and 2-fold, respectively, there does not seem to be an increased risk to develop 
breast cancer specifically13.
Besides the rare Nijmegen breakage syndrome-associated mutations, two common variants in NBS1 (i.e. 
p.E185Q; rs1805794 and c.2265 + 541G > C; rs2735383) have also been reported to be associated with risks for 
several cancer types. Recent meta-analyses for rs1805794 have, however, shown that this variant does not asso-
ciate with breast cancer risk13–16, while associations with lung cancer and urinary system cancer are still incon-
clusive13,16–18. The functional variant rs2735383, localized in in the 3′ UTR of NBS1, has been shown to modulate 
the binding ability of microRNA-629 in lung cancer cells and microRNA-509-5p in colorectal cancer cells, affect 
NBS1 transcriptional activity and decrease NBS1 mRNA and NBS1 protein levels19,20. Although rs2735383 has 
been associated with an increased risk of lung cancer and colorectal cancer13,20, its association with breast cancer 
risk is yet unclear. For this reason, we assessed whether NBS1 rs2735383 is associated with breast cancer risk in 
the Rotterdam Breast Cancer Study (RBCS) by RFLP-PCR and in 45 studies of BCAC through imputation of the 
iCOGS array24.
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Results
To evaluate the association between NBS1 rs2735383 and breast cancer risk, we analyzed NBS1 rs2735383 by 
RFLP-PCR in 1,269 non-BRCA1/2 familial breast cancer patients and 1,159 controls from RBCS. Since genetic 
risk factors are usually enriched in familial/early-onset breast cancer cases, specifically selecting these breast 
cancer patients improves statistical power. Among the cases, 516 had the GG genotype, 507 had the GC genotype 
and 147 had the CC genotype at rs2735383 (minor allele frequency (MAF) = 0.342). Among the controls, 462 
had the GG genotype, 501 had the GC genotype and 114 had the CC genotype (MAF = 0.338). For both cases 
and controls, the genotypes of rs2735383 were in Hardy-Weinberg equilibrium (HWE). Because rs2735383 CC 
was associated with an increased risk of lung cancer and colorectal cancer under a recessive genetic model13,20, 
we analyzed the association of rs2735383 with breast cancer in a similar way. However, rs2735383 was not sig-
nificantly associated with the risk of breast cancer (OR = 1.214, 95% CI = 0.936–1.574, P = 0.144; Table 1). In 
this respect, the lung cancer risk conferred by the rs2735383 CC genotype had been associated with an OR of 
1.28 (95% CI = 1.21–1.46, P < 0.001), whereas the colorectal cancer risk had been associated with an OR of 1.55 
(95% CI = 1.27–1.94, P < 10−4)13,20. Here, we do not observe a similar effect size for breast cancer as for lung and 
colorectal cancer. However, RBCS is underpowered to detect effect sizes smaller than those observed for lung 
cancer (i.e. OR < 1.28). Therefore, we cannot exclude rs2735383 CC is associated with breast cancer, but confers 
a smaller risk.
For this reason we analyzed NBS1 rs2735383 in BCAC studies through imputation. Since we had data available 
for RBCS on rs2735383 from both the PCR-based RFLP and from imputation, we first evaluated the concordance 
between the two methods. In total, from 1,313 samples (i.e. 646 cases and 667 controls) we had genotypes for 
rs2738353 available from both RFLP-PCR and imputation. Importantly, the agreement between the two meth-
ods was 97.1% (i.e. concordance in 1,275 of 1,313 samples, r2 = 0.933) and was similar among cases and con-
trols (i.e. 98.1% versus 96.1%). Moreover, case-control ORs for imputed data were comparable to ORs obtained 
by RFLP-PCR (OR = 1.14, 95% CI = 0.80–1.62 versus OR = 1.17, 95% CI = 0.83–1.66). Therefore, we used the 
imputed data on rs2735383 to evaluate further its association with breast cancer risk.
For the overall analysis in Europeans we had 41,915 cases and 40,042 controls available from 36 case-control stud-
ies. However, rs2735383 was not associated with breast cancer risk in Europeans, neither under a recessive genetic 
model (OR = 1.014, 95% CI = 0.969–1.060, P = 0.556; Table 2 and Fig. 1), nor under a dominant (OR = 1.006, 
95% CI = 0.978–1.035, P = 0.684; Table 2) or additive model (per allele OR = 1.000, 95% CI = 0.979–1.021, 
P = 0.984; Table 2). Because the association with increased lung and colorectal cancer risk was observed in the 
Asian population13,20, we also performed the same analysis in the nine Asian BCAC studies. In total, we had 5,725 
cases and 6,614 controls available for this analysis from nine case-control studies. Also in Asians we did not find 
any association between rs2735383 and breast cancer risk for either the recessive (OR = 0.998, 95% CI = 0.905–
1.100, P = 0.961; Table 2 and Fig. 1), dominant (OR = 0.995, 95% CI = 0.922–1.074, P = 0.900; Table 2) or additive 
genetic model (per allele OR = 0.997, 95% CI = 0.946–1.050, P = 0.911; Table 2). These results imply that NBS1 
rs2735383 is not associated with an increased risk to develop invasive breast cancer.
A previous study had shown that rs2735383 may be associated with breast cancer risk in women > 50 years, 
women with age at menarche > 13 years, women with premenopausal status, women with number of abortions 
≤ 2 and women who have breast fed, but not by age at menopause, number of pregnancies and family history21. 
Therefore, to exclude that an association of rs2735383 with breast cancer risk exists in a particular subgroup of 
Ethnicity Genetic model N Controls N Cases MAF Controls MAF Cases OR (95% CI)* P-value*
European 40,0042 41,915 33.44% 33.39%
Recessive 1.014 (0.969–1.060) 0.556
Dominant 1.006 (0.978–1.035) 0.684
Additive 1.000 (0.979–1.021) 0.984
Asian 6,614 5,725 40.71% 40.58%
Recessive 0.998 (0.905–1.100) 0.961
Dominant 0.995 (0.922–1.074) 0.900
Additive 0.997 (0.946–1.050) 0.911
Table 2.  Association of NBS1 rs2735383 with overall breast cancer risk in the European and Asian BCAC 
studies. N, number of; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. *Adjusted for age, 
study and principal components (PCs). In the European analyses nine PCs were added to the regression model 
and in the Asian analyses two PCs.
Genetic model N Controls N Cases OR (95% CI) P-value
Recessive
GG + GC 963 1023 1
CC 114 147 1.214 (0.936–1.574) 0.144
1077 1170
Table 1.  Association of NBS1 rs2735383 with breast cancer risk in the RBCS study. N, number of; MAF, 
minor allele frequency; OR, odds ratio; CI, confidence interval.
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Figure 1. Forest plots for the association between rs2735383 and breast cancer risk. (A) for the 36 European 
BCAC studies and (B) for the nine Asian BCAC studies. Study-specific ORs (squares) were from a recessive 
genetic model and adjusted by age and PCs. Overall or pooled ORs (diamonds) were from a fixed-effects meta-
analysis.
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individuals or breast cancer patients, we performed subgroup analysis according to age, age at menarche, age at 
menopause, menopausal status, number of full-term pregnancies, breast feeding, family history and receptor 
status. We did, however, not find any association between the genotype at rs2735383 and the risk of breast cancer 
in any of these subgroups for the recessive genetic model (Table 3). Also for the dominant and additive genetic 
models we found no association between the genotype at rs2735383 and breast cancer risk that would withstand 
multiple testing correction (Supplementary Tables S1 and S2). NBS1 rs2735383 is thus not associated with the risk 
for breast cancer, either in the overall analyses or in specific subgroups.
Discussion
The CC genotype of the common variant rs2735383 in the 3′ UTR of NBS1 has been shown to be associated with 
an increased cancer risk, specifically for lung and colorectal cancer (lung cancer: OR = 1.28, 95% CI = 1.21–1.46, 
P < 0.001 and colorectal cancer: OR = 1.55, 95% CI = 1.27–1.94, P < 10−4)13,20. In the current study, we evaluated 
the association of NBS1 rs2735383 with breast cancer risk. We found that the CC genotype of rs2735383 did not 
confer an increased breast cancer risk, neither in the overall analyses nor in the subgroup analyses.
In agreement with these results, a small study by Han et al. consisting of 239 premenopausal breast cancer 
patients and 477 matched controls from the Nurses’ Health Study II showed that rs2735383 did not associate with 
breast cancer risk under an additive genetic model (OR = 0.92, 95% CI = 0.72–1.16, P = 0.469)22. Moreover, the 
study of Wu et al. consisting of 450 breast cancer patients and 450 cancer-free controls from the Henan Province 
in China also found no association with overall breast cancer risk21. However, after stratification according to 
reproductive factors, rs2735383 CC was found to be associated with an increased breast cancer risk for women 
> 50 years, women with age at menarche > 13 years, women with premenopausal status, women with number of 
abortions ≤ 2 and women who have breast fed, but not by age at menopause, number of pregnancies and family 
history21. In the current study we therefore also performed subgroup analysis by age, age at menarche, age at 
menopause, menopausal status, number of full-term pregnancies, breast feeding, family history and receptor 
status, but did not find any association between rs2735383 and risk of breast cancer in any of these subgroups that 
would withstand multiple testing correction. We thus could not replicate the earlier positive findings in women 
> 50 years, women with age at menarche > 13 years, premenopausal women and women who have breast fed. A 
possible, but not very likely, explanation for the difference in outcome between the studies may be the European 
versus Asian ethnicity. In the current study we chose to perform the subgroup analysis only in the European stud-
ies and not the Asian studies as this made sure that we had sufficient power in the subgroup analysis to identify 
smaller effects of rs2735383 on breast cancer risk. In this respect, a more plausible explanation would be that 
subgroup analyses, especially in a small study population (i.e. 450 cases and 450 controls in the study of Wu et al.), 
could have easily given rise to false positive findings. Therefore, one should be careful when reporting positive 
Subgroup N Controls N Cases
MAF 
Controls
MAF 
Cases OR (95% CI)* P-value*
Age
 ≤ 50 years 13,055 13,362 33.76% 33.41% 0.977 (0.899–1.062) 0.581
 > 50 years 26,987 28,553 33.28% 33.38% 1.026 (0.971–1.084) 0.356
Age at menarche
 ≤ 13 years 14,312 13,843 33.72% 33.13% 0.984 (0.914–1.060) 0.677
 > 13 years 8,964 8,095 32.65% 33.63% 1.077 (0.978–1.187) 0.131
Age at menopause
 ≤ 50 years 5,571 7,288 32,79% 33.43% 1.019 (0.906–1.146) 0.755
 > 50 years 3,366 4,262 33.50% 33.24% 0.993 (0.855–1.154) 0.926
Menopausal status
 Premenopausal 8,974 7,412 33.66% 33.07% 0.981 (0.887–1.085) 0.715
 Postmenopausal 19,648 17,353 33.39% 33.56% 1.007 (0.943–1.075) 0.844
Number of full-term pregnancies
 ≤ 2 21,008 19,722 33.53% 33.20% 1.004 (0.942–1.071) 0.893
 > 2 8,258 7,327 33.26% 33.44% 1.032 (0.931–1.144) 0.549
Breast feeding
 No 6,849 6,805 33.36% 33.25% 0.988 (0.884–1.104) 0.828
 Yes 11,947 12,709 33.68% 33.28% 0.978 (0.903–1.060) 0.594
Family history
 1st degree relative with BC 23,648 4,119 33.21% 32.68% 0.990 (0.884–1.108) 0.859
Receptor status
 ER positive 39,699 25,959 33.47% 33.40% 1.021 (0.970–1.075) 0.427
 ER negative 39,618 6,774 33.42% 32.90% 0.991 (0.908–1.082) 0.846
 Triple negative 30,696 2,712 33.10% 32.04% 0.980 (0.847–1.134) 0.788
Table 3. Subgroup analysis of NBS1 rs2735383 and breast cancer risk in the European BCAC studies. N, 
number; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; ER, estrogen receptor; BC, breast 
cancer. *Recessive genetic model adjusted for age, study and nine principal components.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:36874 | DOI: 10.1038/srep36874
findings from multiple small subgroup comparisons and always use appropriate levels of statistical significance23. 
Unfortunately, in the study from Wu et al. there is no mention of multiple testing correction.
It was found that the rs2735383CC genotype significantly decreased the expression of the NBS1 gene 
through either binding of microRNA-629 to the 3′ -UTR of NBS1 gene in lung cancer cells or the binding of 
microRNA-509-5p to the 3′ -UTR of NBS1 gene in colorectal cancer cells19,20. Since low expression of NBS1 may 
reduce the efficiency of DSB repair, this way the rs2735383CC genotype likely confers an increased lung and colorec-
tal cancer risk. According to our study, however, the rs2735383CC genotype does not confer an increased breast 
cancer risk. Considering that in lung and colorectal cancer cells different microRNAs appear to be downregulat-
ing NBS1 expression, tissue specific expression of these microRNAs may likely play a role. Besides microRNA-509 
and microRNA-629, the C allele at rs2735383 has also been predicted to enhance the binding of microRNA-499 
and microRNA-508 to the 3′ UTR of NBS121. However, if these microRNAs are not expressed in normal breast 
tissue, the CC genotype of rs2735383 will not associate with breast cancer risk as NBS1 cannot be downregulated 
by any of these microRNAs. At least in breast cancer cells, none of these microRNAs, except microRNA-629, 
are expressed at substantial levels (source: TCGA Research Network; http://cancergenome.nih.gov/). 
Since microRNAs are often deregulated between normal tissue and cancer tissue, this does not necessarily rep-
resent the situation in normal breast cells. Thus, further evaluation of the miRNA expression levels in normal 
(breast) tissue, but also their correlation with the genotype at rs2735383 should provide more insight for the tissue 
specificity of rs2735383 and cancer risk.
Importantly, in contrast to lung and colorectal cancer susceptibility, the results of this study do not support 
the presence of an association (i.e. OR > 1.04 for Europeans and OR > 1.11 for Asians) between the genotype at 
rs2735383 in the 3′ UTR of NBS1 and breast cancer susceptibility.
Materials and Methods
Study population. RBCS cases (N = 1,269) came from the database of the Clinical Genetics Department 
at Erasmus University Medical Centre in Rotterdam, representing the Southwestern part of the Netherlands. 
First, we selected families that presented with at least two cases of female breast cancer or at least one case of 
female breast cancer and one case of ovarian cancer in first- or second-degree relatives. In addition, at least one of 
these two cases needed to be diagnosed before the age of 60. For each selected family, the youngest breast cancer 
patient who had been tested for BRCA1 and BRCA2 was then assigned to be the index case and included in RBCS. 
Furthermore, breast cancer cases were also included if they were diagnosed either before the age of 40 years with 
unilateral breast cancer or before 50 years of age with bilateral breast cancer and did not report a family history 
of either breast or ovarian cancer in a first or second degree relative. All index cases and their tested relatives did 
not carry a BRCA1 or BRCA2 mutation. The median age of the RBCS cases was 44 years (range 18–92 years). 
RBCS controls (N = 1,159) came from the same database and geographic location as the RBCS cases and included 
women from cystic fibrosis families who were either spouses of individuals at risk of being carrier of a CFTR 
mutation or individuals who were tested negative for a CFTR mutation. The median age of the RBCS controls was 
41 years (range 10–97 years).
BCAC consists of case-control studies of unrelated women24. For the purpose of the current analyses, only 
studies with participants of European and Asian ancestry were included, resulting in a total of 45 case-control 
studies (Supplementary Table S3). Studies with participants of African ancestry (i.e. two studies) were not 
included because power in the analyses would be low due to a relatively low MAF (i.e. 0.123) and small amount 
of cases (i.e. 1,046). Each study was approved by its relevant governing research ethics committee and all study 
participants provided written informed consent. The experimental protocol was approved by the Medical Ethical 
Committee of the Erasmus Medical Center Rotterdam and the study was carried out in accordance with the Code 
of Conduct of the Federation of Medical Scientific Societies in the Netherlands (http://www.fmwv.nl). Following 
genotyping on the iCOGS array24, quality control exclusions (described below), and analysis-specific exclusions, 
data from the following women were available for analysis: 47,640 patients with invasive breast cancer and 46,656 
controls, totaling 94,296 BCAC participants.
PCR-based RFLP analysis. A 324 bp fragment of the 3′ UTR of NBS1 including rs2735383 was amplified 
in a duplex PCR reaction together with a 713 bp fragment of the LRRC4 gene. Primers for NBS1 and LRRC4 were 
present in the PCR reaction at a final concentration of 0.25 and 1 μ M, respectively, and sequences are available 
in Supplementary Table S4. The amplified LRRC4 fragment served as an internal digestion control and gener-
ated two fragments of 549 and 164 bp upon complete digestion with ScfI (New England Biolabs, Frankfurt am 
Main, Germany). The 324 bp amplified NBS1 fragment was only digested when the major G allele was present at 
rs2735383, thereby generating two fragments of 233 and 91 bp. Thus upon successful digestion with ScfI, samples 
with rs2735383 GG generated four fragments, samples with rs2735383 GC generated five fragments and samples 
with rs2735383 CC generated three fragments (Fig. 2).
iCOGS genotyping and imputation. Genotyping of BCAC studies was performed previously using the 
custom iCOGS Illumina Infinium iSelect BeadChip24. Briefly, DNA samples from 114,255 BCAC participants 
were genotyped, along with HapMap2 DNAs for European, African, and Asian populations. Raw intensity data 
files underwent centralized genotype calling and quality control24. The HapMap2 samples were used to identify 
women with predicted European and Asian ancestry by performing principal component (PC) analysis using a 
set of over 37,000 unlinked markers25. Nine European PCs and two Asian PCs were found to control adequately 
for residual population stratification in BCAC data. Samples with a low conversion rate, extreme heterozygosity, 
non-female sex, or one of a first-degree relative pair were excluded. Variants were excluded if they were mono-
morphic or had a call rate < 95% (i.e. when MAF > 0.05) or < 99% (i.e. when MAF < 0.05), deviation from HWE 
(i.e. P < 10–7), or > 2% duplicate discordance.
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Imputation of genotypes was performed using 1000 Genomes Project data (v3 April 2012 release) as the refer-
ence panel26,27. To improve computation efficiency we used a two-step procedure which involved pre-phasing by 
chromosome and by chunk using SHAPEIT software in the first step28 and imputation of the phased data using 
IMPUTE version 2 software in the second29. NBS1 rs2735383 was imputed with an imputation r2 > 0.999 in both 
Europeans and Asians.
Statistical analyses. The association between NBS1 rs2735383 and invasive breast cancer risk was evaluated 
by logistic regression analysis providing ORs and 95% CIs. In the analyses of BCAC studies, ORs were adjusted 
for study, age, and PCs. In the analyses of RBCS, ethnicity was not a confounding factor thus reported ORs were 
unadjusted for PCs. For the European and Asian BCAC studies, we additionally performed study-specific logistic 
regression analysis adjusting for age and PCs, and pooled the log ORs in a fixed-effects meta-analysis. Subgroup 
analyses within the European BCAC studies were based on age (i.e. ≤ 50 years and > 50 years), age at menarche 
(i.e. ≤ 13 years and > 13 years), age at menopause (i.e. ≤ 50 years and > 50 years), menopausal status (i.e. pre-
menopausal and postmenopausal), number of full-term pregnancies (i.e. ≤ 2 and > 2), breast feeding (i.e. no 
and yes), first-degree family history of breast cancer and receptor status (i.e. ER positive, ER negative and triple 
negative). Clinical and demographic characteristics of the BCAC cases are presented in Supplementary Table S5. 
Association between NBS1 rs2735383 and the clinical and demographic characteristics were evaluated using a 
χ 2 test. All P-values were two-sided and P < 0.05 was considered to be statistically significant after correction for 
multiple testing by the Bonferroni procedure. Logistic regression analyses were performed using SPSS statistics 
version 23 (IBM Corporation, Armonk, NY) and fixed-effects meta-analyses using Stata version 13 (StataCorp, 
College Station, TX).
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